Parameters | PATIENTS | ||
---|---|---|---|
Postoperative IMRT | Definitive IMRT | ||
N patients | 116 | 44 | |
concomittant systemic therapy | 78 (67%) | 30 (68%) | |
Induction chemotherapy | 2 (2%) | 5 (11%) | |
Gender, male / female | 69% / 31% | 57% / 43% | |
Age, mean / median (range) | 59 / 58 (25–90) years | 66 / 64 (41–85) years | |
WHO performance status 0, 1, 2 | 83%, 13%, 4% | 62%, 34%, 4% | |
Histology: | squamous cell carcinoma | 114 (98%) | 43 (98%) |
adenoid cystic carcinoma (ACC) | 0 | 1 | |
Merkel cell carcinoma | 2 (2%) | 0 | |
Localization: | T/FoM | 74 (64%) | 30 (68%) |
mandible/alveolar process/TR | 32 (28%) | 7 (16%) | |
buccal mucosa (cheek) | 8 (7%) | 4 (9%) | |
others (lip, palate) | 2 (2%) | 3(7%) | |
T stage: | rT0 | 9 (8%) | 0 |
rT+ | 17 (15%) | 10 (23%) | |
T1 | 16 (14%) | 1 (2%) | |
T2 | 35 (30%) | 6 (14%) | |
T3 | 10 (9%) | 6 (14%) | |
T4 | 29 (25%) | 21 (48%) | |
N stage: | rN0 | 5 (4%) | 2 (5%) |
rN+ | 15 (13%) | 2 (5%) | |
N0 | 36 (31%) | 12 (27%) | |
N 1a-2b | 44 (38%) | 13 (30%) | |
N2c | 10 (9%) | 15 (34%) | |
N3 | 1 (1%) | 0 | |
Stage | I | 5 (4%) | 0 |
II | 10 (9%) | 0 | |
III | 17 (15%) | 1 (2%) | |
IV | 57 (49%) | 33 (75%) | |
nodal or primary recurrence | 27 (23%) | 10 (23%) | |
Follow up, mean/median (range) | all patients | 33 / 18 (2–101) months | 20 / 12 (1–87) months |
alive patients | 35 / 35 (2–101) months | 33 / 22 (5–87) months | |
dead patients | 24 / 22 (5–66) months | 12 / 8 (3–27) months |